Antiplatelet (reversible P2Y12 inhibitor)

Ticagrelor

Brand names: Brilique

Ticagrelor is an antiplatelet (P2Y12 inhibitor) used with aspirin after acute coronary syndromes.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

US labelling (FDA)

Reference — US labelling, may differ from UK

ACS or History of MI Initiate treatment with 180 mg oral loading dose of ticagrelor tablets. Then administer 90 mg twice daily during the first year. After one year, administer 60 mg twice daily. ( 2.2 ) Patients with CAD and No Prior Stroke or MI Administer 60 mg ticagrelor tablets twice daily. ( 2.3 ) Acute Ischemic Stroke Initiate treatment with a 180 mg loading dose of ticagrelor tablets then continue with 90 mg twice daily for up to 30 days. ( 2.4 ) Use ticagrelor tablets with a daily maintenance dose of aspirin of 75 to 100 mg. ( 2 ) However, in patients who have undergone PCI, consider single antiplatelet therapy with ticagrelor tablets based on the evolving risk for thrombotic …

Source: US FDA prescribing information (openFDA / DailyMed), label dated 2025-10-28. Accessed 2026-06-12. US dosing and indications can differ from UK practice — use UK sources for prescribing decisions.

Clinical monograph

How it works

It reversibly inhibits the platelet P2Y12 receptor and, unlike clopidogrel, is not a pro-drug — giving a faster, more consistent effect.

Prescribing in practice

Dyspnoea is a characteristic and usually benign side effect, but should be assessed.
Keep concurrent aspirin low-dose — higher aspirin doses reduce its benefit; it is taken twice daily.
It can cause bradyarrhythmias and ventricular pauses; bleeding risk; it interacts with strong CYP3A inhibitors/inducers.

Monitoring

Watch for bleeding and breathlessness; reinforce adherence to twice-daily dosing.

Counselling the patient

Take it twice a day, and keep to low-dose aspirin.
Breathlessness can occur and often settles — but report it.
Report bleeding; don't stop it without advice.

Evidence & guidelines

Reduced cardiovascular events versus clopidogrel after ACS (PLATO; NICE TA236).

Reference: PLATO trial; PEGASUS-TIMI trial; ESC NSTEMI/STEMI Guidelines; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Curated clinical cross-links plus same-class fallbacks.

Calculators

Pathways